Type 1 diabetes: pathogenesis and prevention

被引:218
作者
Gillespie, Kathleen M. [1 ]
机构
[1] Univ Bristol, Dept Clin Sci, Bristol, Avon, England
关键词
D O I
10.1503/cmaj.060244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1 diabetes results from the autoimmune destruction of insulin-producing beta cells in the pancreas. Genetic and, as yet undefined, environmental factors act together to precipitate the disease. The excess mortality associated with the complications of type 1 diabetes and the increasing incidence of childhood type 1 diabetes emphasize the importance of therapeutic strategies to prevent this chronic disorder. Why is it considered that type 1 diabetes might be preventable? Different strands of diabetes research are coming together to suggest therapeutic targets. Islet cell autoantibody assays make it possible to accurately identify people at risk of future disease. In most cases, a long prodrome provides a window of opportunity to reverse the autoimmune process. Although no current "cure" exists, recent genetic data and preliminary trial results suggest T cells as a target for preventive strategies. Another potentially attainable target is induction of tolerance to the beta-cell proteins such as insulin that are inappropriately recognized. Other strategies involve beta-cell replacement, but currently there are insufficient donor cells available. This may be overcome as the processes controlling the differentiation of pancreatic and nonpancreatic progenitors as well as replication of existing islet beta cells are unravelled.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 77 条
  • [1] Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics
    Achenbach, P
    Warncke, K
    Reiter, J
    Naserke, HE
    Williams, AJK
    Bingley, PJ
    Bonifacio, E
    Ziegler, AG
    [J]. DIABETES, 2004, 53 (02) : 384 - 392
  • [2] Association of CTLA4 polymorphism with regulatory T cell frequency
    Atabani, SF
    Thio, CL
    Divanovic, S
    Trompette, A
    Belkaid, Y
    Thomas, DL
    Karp, CL
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (07) : 2157 - 2162
  • [3] Infections and autoimmune diseases
    Bach, JF
    [J]. JOURNAL OF AUTOIMMUNITY, 2005, 25 : 74 - 80
  • [4] REVELATION OF SPECIFICITY OF 64K AUTOANTIBODIES IN IDDM SERUMS BY HIGH-RESOLUTION 2-D GEL-ELECTROPHORESIS - UNAMBIGUOUS IDENTIFICATION OF 64K TARGET ANTIGEN
    BAEKKESKOV, S
    WARNOCK, G
    CHRISTIE, M
    RAJOTTE, RV
    LARSEN, PM
    FEY, S
    [J]. DIABETES, 1989, 38 (09) : 1133 - 1141
  • [5] Comparative genetics of type 1 diabetes and autoimmune disease - Common loci, common pathways?
    Becker, KG
    [J]. DIABETES, 1999, 48 (07) : 1353 - 1358
  • [6] A POLYMORPHIC LOCUS NEAR THE HUMAN INSULIN GENE IS ASSOCIATED WITH INSULIN-DEPENDENT DIABETES-MELLITUS
    BELL, GI
    HORITA, S
    KARAM, JH
    [J]. DIABETES, 1984, 33 (02) : 176 - 183
  • [7] SUSCEPTIBILITY TO HUMAN TYPE-1 DIABETES AT IDDM2 IS DETERMINED BY TANDEM REPEAT VARIATION AT THE INSULIN GENE MINISATELLITE LOCUS
    BENNETT, ST
    LUCASSEN, AM
    GOUGH, SCL
    POWELL, EE
    UNDLIEN, DE
    PRITCHARD, LE
    MERRIMAN, ME
    KAWAGUCHI, Y
    DRONSFIELD, MJ
    POCIOT, F
    NERUP, J
    BOUZEKRI, N
    CAMBONTHOMSEN, A
    RONNINGEN, KS
    BARNETT, AH
    BAIN, SC
    TODD, JA
    [J]. NATURE GENETICS, 1995, 9 (03) : 284 - 292
  • [8] Diabetes antibody standardization program: First assay proficiency evaluation
    Bingley, PJ
    Bonifacio, E
    Mueller, PW
    [J]. DIABETES, 2003, 52 (05) : 1128 - 1136
  • [9] Prediction of IDDM in the general population - Strategies based on combinations of autoantibody markers
    Bingley, PJ
    Bonifacio, E
    Williams, AJK
    Genovese, S
    Bottazzo, GF
    Gale, EAM
    [J]. DIABETES, 1997, 46 (11) : 1701 - 1710
  • [10] Optimized autoantibody-based risk assessment in family members - Implications for future intervention trials
    Bingley, PJ
    Williams, AJK
    Gale, EAM
    [J]. DIABETES CARE, 1999, 22 (11) : 1796 - 1801